The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis

Abstract Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate COVID-19 vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) h...

Повний опис

Бібліографічні деталі

Автори:	Shaymaa Glhoom, Aya Fergany, Dina El-Araby, Asmaa A. Abdelkhalek, Asmaa Gomaa, Eman O. Zayed, Mohamed Abd-ElGwad
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2024-01-01
Серія:	European Journal of Medical Research
Предмети:	Cilgavimab Tixagevimab Evusheld AZD7442 COVID-19
Онлайн доступ:	https://doi.org/10.1186/s40001-023-01549-x
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!